60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Up 40.4% in June

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 323,400 shares, a growth of 40.4% from the May 31st total of 230,400 shares. Based on an average trading volume of 472,400 shares, the days-to-cover ratio is presently 0.7 days. Currently, 3.5% of the company’s stock are sold short.

60 Degrees Pharmaceuticals Stock Down 2.7 %

Shares of 60 Degrees Pharmaceuticals stock traded down $0.01 during trading on Monday, hitting $0.25. The stock had a trading volume of 96,970 shares, compared to its average volume of 412,981. The stock has a 50 day simple moving average of $0.26 and a 200 day simple moving average of $0.42. The company has a market capitalization of $3.00 million and a PE ratio of -0.24. 60 Degrees Pharmaceuticals has a 1 year low of $0.20 and a 1 year high of $8.65.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last announced its quarterly earnings data on Wednesday, May 15th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.19. The company had revenue of $0.08 million for the quarter. As a group, equities analysts expect that 60 Degrees Pharmaceuticals will post -0.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Thursday, June 6th.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.